The association of socioeconomic status with receipt of neoadjuvant chemotherapy
Author:
Funder
Patient-Centered Outcomes Research Institute
National Institute on Minority Health and Health Disparities
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/article/10.1007/s10549-018-4954-0/fulltext.html
Reference28 articles.
1. Killelea BK, Yang VQ, Wang S-Y et al (2015) Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the national cancer data base. J Clin Oncol 33:4267–4276
2. Mougalian SS, Soulos PR, Killelea BK et al (2015) Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 121:2544–2552
3. Gradishar WJ, Anderson BO, Balassanian R et al (2017) NCCN clinical practice guidelines in oncology: breast cancer version 3
4. Weeks JC, Uno H, Taback N et al (2014) Interinstitutional variation in management decisions for treatment of 4 common types of cancera multi-institutional cohort study interinstitutional variation in cancer management decisions. Ann Intern Med 161:20–30
5. Onitilo AA, Onesti JK, Single RM et al (2013) Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer. PloS ONE 8:e84535
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Assessment of Treatment Sequence in Patients With Stage III Breast Cancer;Journal of Surgical Research;2024-10
2. Axillary Management Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer;Clinical Breast Cancer;2024-08
3. Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer;Breast Cancer Research and Treatment;2023-12-09
4. Treatment utilization and effectiveness of neoadjuvant chemotherapy comparing men and women diagnosed with breast cancer: a Swedish retrospective cohort study;Breast Cancer Research and Treatment;2023-10-09
5. Reduced Risk of All-Cause, Cancer-, and Cardiovascular Disease-Related Mortality among Patients with Primary Malignant Cardiac Tumors Receiving Chemotherapy in the United States;Current Oncology;2023-09-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3